Boston Scientific Reports Exceptional 2025 Revenue Growth Driven by Cardiovascular Innovation

Boston Scientific credits innovation for exceptional 2025 revenue growth

Innovation Drives Cardiovascular-Led Revenue Surge

Boston Scientific posts fourth-quarter net sales of $5.286 billion, marking a 15.9% reported increase and a 12.7% organic rise versus a year earlier, and closes 2025 with full‑year net sales of $20.074 billion, up 19.9% reported and 15.8% organic. Management says reported fourth‑quarter sales exceed its guidance band and that global teams deliver differentiated innovation and execution that drive patient impact and market share gains. The company frames 2025 as an exceptional year that both outperforms targets and positions it for sustained growth.

The revenue performance is concentrated in the Cardiovascular franchise, which grows 18.2% reported and 16.1% organic in the quarter, while the MedSurg portfolio posts 11.7% reported growth and 6.5% organic growth. Regionally, the U.S. market expands 17.0% reported and operational, with EMEA advancing 12.4% reported and 4.8% operational. Boston Scientific points to new product introductions and continued commercial execution as key drivers of the cardiovascular strength and broader top‑line momentum across markets.

Executives underscore continued investment in research and development, disciplined operations and targeted product launches to sustain revenue and margin expansion. CEO Mike Mahoney emphasizes that innovation and performance are driving measurable patient impact and setting the company up for future growth. The company also notes a strategic product decision earlier in the year to discontinue worldwide sales of the ACURATE neo2™ and ACURATE Prime™ valves in Q2 2025, a move it presents as part of portfolio management and operational focus.

Earnings and guidance nuance

On profitability, Boston Scientific reports GAAP net income attributable to common stockholders of $672 million, or $0.45 per share, in the fourth quarter and $2.898 billion, or $1.94 per share, for the full year. Adjusted earnings per share for the quarter are $0.80, modestly above the company’s own adjusted guidance, while reported GAAP EPS slightly trails the prior guidance range.

Patient impact and strategic priorities

The company highlights that millions of patients benefit from its devices and that continued market development, new product launches and disciplined investments underpin its aim to expand margins and franchise leadership in both MedSurg and Cardiovascular segments globally.